Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background A complete remission is essential for prolonging survival in patients with acute
myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the …

To assess the frequency of TP53 alterations and their correlation with other genetic changes
and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed …

To study the characteristics and clinical impact of therapy-related acute myeloid leukemia (t-AML).
200 patients (7.0%) had t-AML and 2653 de novo AML (93%). Patients with t-AML …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

… Salih, Gerhard Held, David Nachbaur, Marie von Lilienfeld-Toal, Ulrich Germing, Detlef
Haase, Hans-Günther Mergenthaler, Jürgen Krauter, Arnold Ganser, Gudrun Göhring …

The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but
not yet demonstrated in a randomised‐controlled trial. A systematic review of the published …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS-…

Purpose The tet oncogene family member 2 (TET2) gene was recently identified to be mutated
in myeloid disorders including acute myeloid leukemia (AML). To date, there is increasing …

Purpose Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)]
is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical …